amifostine anhydrous has been researched along with Peripheral Nerve Diseases in 7 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Breast cancer patients receiving high-dose infusional paclitaxel (725 mg/m(2)/24 h) in combination with doxorubicin (165 mg/m(2)/96 h) and cyclophosphamide (100 mg/kg/2 h; ACT) were studied on two autologous peripheral blood stem cell transplant protocols, one with and one without amifostine (740 mg/m(2) administered over 10 min before and 12 h after initiation of the paclitaxel infusion)." | 3.72 | Neurophysiological study of peripheral neuropathy after high-dose Paclitaxel: lack of neuroprotective effect of amifostine. ( Beamon, K; Doroshow, JH; Forman, S; Longmate, J; Margolin, K; Morgan, R; Openshaw, H; Shibata, S; Slatkin, NE; Somlo, G; Synold, TW, 2004) |
| " At baseline, before each treatment cycle, and for 3 months after completing chemotherapy, patients were evaluated for evidence of neurotoxicity and other treatment-related adverse effects using three methods: standard clinical evaluation (National Cancer Institute common toxicity criteria [CTC] grading), a neurotoxicity questionnaire to assess symptoms and limitations imposed by peripheral neuropathy, and vibration perception threshold (VPT) testing." | 2.71 | Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group. ( Almadrones, L; Cella, DF; Donnelly, J; Herzog, TJ; McGuire, WP; Moore, DH; Waggoner, SE, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Pereira, AF | 1 |
| Lino, JA | 1 |
| Alves, BWF | 1 |
| Lisboa, MRP | 1 |
| Pontes, RB | 1 |
| Leite, CAVG | 1 |
| Nogueira, RB | 1 |
| Lima-Júnior, RCP | 1 |
| Vale, ML | 1 |
| Cavaletti, G | 2 |
| Zanna, C | 1 |
| Moore, DH | 1 |
| Donnelly, J | 1 |
| McGuire, WP | 1 |
| Almadrones, L | 1 |
| Cella, DF | 1 |
| Herzog, TJ | 1 |
| Waggoner, SE | 1 |
| Openshaw, H | 1 |
| Beamon, K | 1 |
| Synold, TW | 1 |
| Longmate, J | 1 |
| Slatkin, NE | 1 |
| Doroshow, JH | 1 |
| Forman, S | 1 |
| Margolin, K | 1 |
| Morgan, R | 1 |
| Shibata, S | 1 |
| Somlo, G | 1 |
| Albers, J | 1 |
| Chaudhry, V | 1 |
| Donehower, R | 1 |
| Selvaratnam, G | 1 |
| Philips, RH | 1 |
| Mohamed, AK | 1 |
| Radzi, A | 1 |
| Penz, M | 1 |
| Kornek, GV | 1 |
| Raderer, M | 1 |
| Ulrich-Pur, H | 1 |
| Fiebiger, W | 1 |
| Scheithauer, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Limited Access Trial Using Amifostine for Protection Against Cisplatin and 3-Hour Paclitaxel-Induced Neurotoxicity[NCT00003624] | Phase 2 | 0 participants | Interventional | 1998-12-31 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for amifostine anhydrous and Peripheral Nerve Diseases
| Article | Year |
|---|---|
Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity.
Topics: Amifostine; Antineoplastic Agents; Forecasting; Glutathione; Growth Inhibitors; Humans; Insulin-Like | 2002 |
Interventions for preventing neuropathy caused by cisplatin and related compounds.
Topics: Adrenocorticotropic Hormone; Amifostine; Antineoplastic Agents; Cisplatin; Ditiocarb; Glutathione; H | 2007 |
Adverse effects of cytotoxics-platinum agents.
Topics: Amifostine; Antineoplastic Agents; Carboplatin; Cisplatin; Humans; Kidney Diseases; Neoplasms; Perip | 1997 |
1 trial available for amifostine anhydrous and Peripheral Nerve Diseases
| Article | Year |
|---|---|
Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Agents, Phytogenic; Antineoplastic Combin | 2003 |
3 other studies available for amifostine anhydrous and Peripheral Nerve Diseases
| Article | Year |
|---|---|
Amifostine protects from the peripheral sensory neuropathy induced by oxaliplatin in mice.
Topics: Amifostine; Animals; Antineoplastic Agents; Hyperalgesia; Male; Mice; Oxaliplatin; Peripheral Nervou | 2020 |
Neurophysiological study of peripheral neuropathy after high-dose Paclitaxel: lack of neuroprotective effect of amifostine.
Topics: Adult; Amifostine; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Ag | 2004 |
Subcutaneous administration of amifostine: a promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy.
Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Colorectal Neoplasms; Female; Humans; Injections, Su | 2001 |